In this week’s edition of InnovationRx, we look at Phil Knight’s big cancer gift, Medallion’s credentialing clearinghouse, a ...

NeuroOne stock rallies after FDA clears its OneRF system, a minimally invasive solution targeting severe facial pain, scheduled to launch in late 2025.

NeuroOne has obtained 510(k) clearance from the FDA for its OneRF trigeminal nerve ablation system to treat facial pain.

Neuroone Medical Technologies Corp. expanded into treatment of chronic pain with a new U.S. FDA clearance for use of its Onerf system to treat trigeminal nerve pain. The system uses radiofrequency ...

Trigeminal nerve ablation, a minimally invasive procedure, uses RF energy to destroy abnormal tissue and relieve severe, ...

FDA Clearance Further Validates Technology Platform and Offers Alternatives to Pharmaceutical and Invasive Surgical Treatments EDEN PRAIRIE, Minn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical ...

Technologies has received U.S. Food and Drug Administration, FDA, clearance to market its OneRF Trigeminal Nerve Ablation ...

Good day, ladies and gentlemen. Welcome to the Third Quarter of Fiscal Year 2025 and financial results conference Call for NeuroOne Medical Technologies Corporation. Today’s call will […] ...

NeuroOne Medical Technologies(NASDAQ:NMTC) reported fiscal third quarter 2025 earnings on August 14, 2025, with product revenue up 105% year-over-year to $1.7 million and product gross margins rising ...

Ronald W. McClurg, CFO, said, "product revenue increased 105% to $1.7 million" and cited "sizable improvements year-over-year ...

Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 ...

Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: ...